Shanghai CureGene Pharmaceutical

Shanghai CureGene Pharmaceutical is a clinical-stage biotechnology company founded in 2018 and headquartered in Shanghai, China, with additional R&D operations in the United States. The company specializes in the discovery and development of innovative small molecule and nucleic acid-based therapies, primarily focusing on cardio-cerebrovascular and antiviral diseases. Its lead program, CG-0255 (evategrel), is a next-generation P2Y12 receptor antagonist designed as a thioether hydrolysis-based prodrug for the treatment of acute coronary syndrome and stroke. CureGene's diversified pipeline also features CG-0416, a liver-targeted THR-beta agonist for metabolic dysfunction-associated steatohepatitis (MASH), and CG-1999, an immunomodulator aimed at achieving a functional cure for chronic hepatitis B. The leadership team comprises industry veterans with extensive experience from global pharmaceutical companies such as Gilead Sciences.